<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413 / 2313-8955-2014-1-1-12-19</article-id><article-id pub-id-type="publisher-id">225</article-id><article-categories><subj-group subj-group-type="heading"><subject>Archive categories</subject></subj-group></article-categories><title-group><article-title>CHOICE OF ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE PATIENTS WITH CRITICAL CORONARY ARTERY STENOSIS</article-title><trans-title-group xml:lang="en"><trans-title>CHOICE OF ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE PATIENTS WITH CRITICAL CORONARY ARTERY STENOSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Osipova</surname><given-names>Ol'ga А.</given-names></name><name xml:lang="en"><surname>Osipova</surname><given-names>Ol'ga А.</given-names></name></name-alternatives><email>OOsipova@gnicpm.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Suyazova</surname><given-names>Svetlana B.</given-names></name><name xml:lang="en"><surname>Suyazova</surname><given-names>Svetlana B.</given-names></name></name-alternatives><email>pol8bel@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Nagibina</surname><given-names>Anna I.</given-names></name><name xml:lang="en"><surname>Nagibina</surname><given-names>Anna I.</given-names></name></name-alternatives><email>inscreen@mail.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2014</year></pub-date><volume>1</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2014/1/selection_3.pdf" /><abstract xml:lang="ru"><p>Sixty patients with stages II-III AH were studied. ABPM was performed in all the patients. DBPP was assessed by the degree of nocturnal BP lowering. Patients were randomized into groups receiving perindopril or losartan potassium. Perindopril was prescribed at a dose of 4 mg/day with subsequent rising up to 8 mg/day during 7 days. The initial dose of losartan potassium was 25 mg with subsequent rising up to 50 mg 2 times a day. The duration of observation was 8 weeks. Thus, perindopril therapy in hypertensive patients in the preoperative CABG period increased the number of people with normal BP profile.</p></abstract><trans-abstract xml:lang="en"><p>Sixty patients with stages II-III AH were studied. ABPM was performed in all the patients. DBPP was assessed by the degree of nocturnal BP lowering. Patients were randomized into groups receiving perindopril or losartan potassium. Perindopril was prescribed at a dose of 4 mg/day with subsequent rising up to 8 mg/day during 7 days. The initial dose of losartan potassium was 25 mg with subsequent rising up to 50 mg 2 times a day. The duration of observation was 8 weeks. Thus, perindopril therapy in hypertensive patients in the preoperative CABG period increased the number of people with normal BP profile.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Osipova OA</kwd><kwd>Suyazova SB</kwd><kwd>Nagibina AI. Choice of antihypertensive therapy in hypertensive patients with critical coronary artery stenosis. Research Result. Medicine and Pharmacy Series. 2014</kwd><kwd>1(1):12-19 (In Russian). DOI: 10.18413 / 2313-8955-2014-1-1-12-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Osipova OA</kwd><kwd>Suyazova SB</kwd><kwd>Nagibina AI. Choice of antihypertensive therapy in hypertensive patients with critical coronary artery stenosis. Research Result. Medicine and Pharmacy Series. 2014</kwd><kwd>1(1):12-19 (In Russian). DOI: 10.18413 / 2313-8955-2014-1-1-12-19</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>D&amp;iacute;ez J. Arterial Hypertension in Patients with Heart Failure // Heart Fail. Clin. 2014. N 10 (2). pp. 233-242.</mixed-citation></ref><ref id="B2"><mixed-citation>Zelveyan P.A., Oshepkova E.V., Buniatyan M.S. Circadian Rhythm of Blood Pressure and the State of Target Organs in Patients with Mild and Moderate forms of Essential Hypertension // Ter. Architect. 2001. N 2. P. 33-38.</mixed-citation></ref><ref id="B3"><mixed-citation>Comparative Analysis of the Ambulatory Blood Pressure Monitoring Parameters in Patients with Arterial Hypertension and Chronic Heart Failure / Osipova O.A., Suiazova S.B., Vlasenko M.A., Godlevska O.M. // Fundamental Research. 2012. N. 7. pp. 146-150.</mixed-citation></ref><ref id="B4"><mixed-citation>Dahlof B., Devereux R.B., Kjeldsen S.E. Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a Randomized Trial Against Atenolol // The Lancet. 2002. N 359. pp. 995-1003.</mixed-citation></ref><ref id="B5"><mixed-citation>The Goal of Blood Pressure in the Hypertensive Patient with Diabetes is Defined: now the Challenge is to go from Recommendations to Practice / Lopez-Jaramillo P., Lopez-Lopez J., Lopez-Lopez C., Rodriguez-Alvarez M.I. // Diabetol. Metab. Syndr. 2014. N 4. 6 (1). pp. 31.&amp;nbsp;</mixed-citation></ref><ref id="B6"><mixed-citation>Prestance for Correction of Endothelial Dysfunction in Patients with Acute Ischemic Stroke / Pribylova N.N., Bezzubtseva M.V., Sotnikova S.Yu., Semidotskaya I.Yu., Pribylov S.A. // Medical Business / № 3 2013/ pp. 32-35.</mixed-citation></ref><ref id="B7"><mixed-citation>Alhenc-Gelas F., Tsai S., Callahan K.S. Stimulation of Prostaglandin Formation by Vasoactive Mediators in Cultured Human Endothelial cells // Basic Res. Cardiol. 1982. N 24. pp. 723-742.</mixed-citation></ref><ref id="B8"><mixed-citation>Stroke in Coronary Artery Bypass Graft Surgery: an Analysis of the CASS Experience. The Participants in the Coronary Artery Surgery Study / Frye R.L., Kronmal R., Schaff H.V., Myers W.O. Int. J. Cardiol. 1992. N. 36. pp. 213-221.</mixed-citation></ref><ref id="B9"><mixed-citation>Lupanov V.P. Angiotensin-converting Enzyme Inhibitors in the Treatment and Prognosis of CHF Patients with Ischemic Heart Disease. Focus on Ramipril // Hypertension. 2010. N. 1 (9). pp. 45-50.</mixed-citation></ref><ref id="B10"><mixed-citation>Lapach S.N., Chubenko A.V., Babich P.N. Statistical Methods in Biomedical Research Using Exel. 2 Ed.: MORION. 2001. 408 p.</mixed-citation></ref><ref id="B11"><mixed-citation>Fagard R.H., Celis H. Prognostic Significance of Various Characteristics of Out-of-the-Office Blood Pressure // J. Hypertens. 2004. Vol. 22. pp. 1663-1666.</mixed-citation></ref><ref id="B12"><mixed-citation>Effects of an Angiotensin-Converting-Enzyme Inhibitor on Cardiovascular Events in High-Risk Patients. HOPE Study Investigators. // N. Engk. J. Med. 2000. 342. pp. 145-153.</mixed-citation></ref><ref id="B13"><mixed-citation>European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension 2007 // J. Hypertens. 2007. Vol. 25. pp. 1101-1187.</mixed-citation></ref><ref id="B14"><mixed-citation>Diagnosis and Treatment of Arterial Hypertension. Russian Recommendations (third revision). Formulated by the Committee of Experts of the Russian Medical Society on Arterial Hypertension and All-Russian Society of Cardiologists. Moscow, 2008.</mixed-citation></ref><ref id="B15"><mixed-citation>Bulkina O.S., Talitskiĭ K.A., Karpov Iu.A. // Hypertrophy Of Left Ventricular Myocardium As Modifiable Risk Factor: New Possibilities Of Correction. Kardiologiya. 2006. N. 46 (3). pp. 68-72.</mixed-citation></ref></ref-list></back></article>